Marcus Jamil, MD
Urology · Plymouth, MINPI 1063948982
Payments from drug & device makers
What this record shows
This record is dominated by grants: $100,000 of the $102,755 with a category attached, or 97.3%. Boston Scientific accounts for 99.7% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2023 at $51,984 and has fallen 99.6% since, to $187 in 2025. Among urology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 30 payments — averaging $3425.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$102K
- Coloplast$116
- Laborie Medical Technologies Corp.$112
- Conmed Corporation$45
- Endo USA, Inc.$44
- Myovant Sciences Inc.$21
- plus $14 from 1 others
What the payments were for
- Grants$100,00097%
- Travel & lodging$1,2431%
- Food & beverage$1,2321%
- Education$2800%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 21 | $102,404 |
| Coloplast | 3 | $116 |
| Laborie Medical Technologies Corp. | 1 | $112 |
| Conmed Corporation | 1 | $45 |
| Endo USA, Inc. | 2 | $44 |
| Myovant Sciences Inc. | 1 | $21 |
| Tolmar, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$102,755 in reported general payments places this provider in the 95th percentile of 400 urology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 47 | $54,629 |
| Mirabegron ErMirabegron | 20 | $15,771 |
| Trospium Chloride | 38 | $2,704 |
| Tamsulosin Hcl | 119 | $2,125 |
| Estradiol | 11 | $494 |
| Finasteride | 18 | $377 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 16 | $114 |
| Ciprofloxacin Hcl | 42 | $105 |
| Cephalexin | 34 | $101 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $15 |
Paid to pharmacies, not to this prescriber.
Other urology in Plymouth
- Ashok ReddySterling Heights$4.9M
- William RobertsAnn Arbor$973K
- Kenneth KernenTroy$910K
- William JohnstonLivonia$675K
- Jason HafronWest Bloomfield$490K
- Khurshid GhaniAnn Arbor$413K
- Richard BennettRoyal Oak$361K
- Ryan NelsonUtica$296K
- Casey DauwAnn Arbor$188K
- Aram LoebDetroit$112K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.